 |
市场调查报告书
商品编码
1273415
无创呼吸机市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)Non-invasive Ventilators Market - Growth, Trends, and Forecasts (2023 - 2028) |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
在预测期内，无创通气 (NIV) 市场的复合年增长率预计为 5.9%。
COVID-19 大流行的爆发对研究市场产生了重大影响。 突然爆发的大流行最初对市场产生了短期的负面影响，因为到医院和诊所就诊的患者减少了。 然而，在大流行后期，COVID-19 患者和其他慢性呼吸道疾病患者对 NIV 的需求增加，市场出现显着增长。 根据 2021 年 3 月发表在《临床呼吸杂誌》上的研究结果，NIV 与持续气道正压通气 (CPAP) 一起被广泛用于治疗中度至重度急性呼吸衰竭 (ARF) 患者。 此外，在一项针对中度至重度 COVID-19 感染患者的研究中，NIV 在总研究人群中的成功率为 48%，NIV 后重症监护病房 (ICU) 潜伏患者的存活率为 57%。得出的结论是，它已经被证实。 因此，目标患者的高生存率增加了对 NIV 的需求。 这对市场增长做出了重大贡献，预计在预测期内将继续增长。
预计在预测期内，呼吸系统疾病患者数量的增加和对非侵入性手术的需求激增等因素将推动市场增长。 此外，与各种类型的无创 (NIV) 呼吸机相关的优势也是增加设备采用和推动市场增长的因素。
慢性呼吸道疾病会影响呼吸道和肺部的其他部位。 呼吸道症状是初级保健中心就诊的主要原因之一。 主要可预防的慢性呼吸道疾病包括哮喘、慢性阻塞性肺疾病（COPD）、过敏性鼻炎、睡眠呼吸暂停和结核病（主要是耐多药结核病）。 这些患者需要机械通气以获得更好的结果。 根据 2022 年 6 月发表在 NCBI 上的一篇文章，无创正压通气可在正压下为肺部充氧，无需气管插管，可用于急性和慢性呼吸衰竭。
此外，正如 2022 年 6 月在 LLICM 上发表的一篇论文所述，NIV 已成功用于术后低氧血症。 此外，面罩 NIV 已被证明可以改善气体交换，减少呼吸问题，并改善患有慢性阻塞性肺病 (COPD)、因肥胖引起的换气过度呼吸衰竭和心源性肺水肿的患者的临床结果。已知可以改善 因此，该系统的相关优势正在增加这些设备的采用，这有望推动市场的增长。
但是，与呼吸机相关的并发症和副作用（例如感染肺炎的风险）可能会降低产品采用率并阻碍市场增长。
无创通气的市场趋势
COPD 和哮喘预计在预测期内将显着增长
慢性阻塞性肺病是一种危及生命的进行性肺部疾病，会导致呼吸急促（最初是在用力时）并且容易恶化。 此外，严重的病例可能会增加长期紧急治疗的需要。 此外，哮喘是在受试者中发现的最常见但复杂的异质性炎症性气道疾病之一。 因此，预计哮喘和慢性阻塞性肺病等呼吸急症的大量发生将增加 NIV 的应用并加速该细分市场的增长。
根据 2022 年 9 月发表在《美国呼吸与重症监护医学杂誌》上的一篇论文，全球每年有近十分之一的人患有慢性阻塞性肺病。 而根据慢性阻塞性肺病全球倡议组织在2022年世界肺日发布的数据，上一年估计有近2亿人患上COPD，哮喘每年影响约2.62亿人，是常见的呼吸系统疾病之一。 多项研究表明，NIV 对患有哮喘和慢性阻塞性肺病的人群具有更多积极益处。 因此，疾病的高负担预计会产生对 NIV 采用的需求，从而推动该领域的增长。
此外，根据 2022 年 5 月发表在美国转化研究杂誌 (AJTR) 上的一篇论文，异丙托溴铵与无创通气相结合可有效治疗慢性阻塞性肺病和呼吸衰竭患者。 该系统可显着改善循环炎症，改善患者肺功能和血气浓度，取得更大疗效。 因此，该系统的这些优势有望在预测期内推动该细分市场的增长。 因此，该系统在治疗 COPD 患者方面的优势和应用有望在参与者之间创造竞争力，并有助于该领域的增长。
预计在预测期内北美将占据主要市场份额
预计北美将占据很大的市场份额，并且预计在预测期内其增长将继续。 推动该地区市场增长的主要因素是各种呼吸系统疾病的流行和产品批准数量的增加。
呼吸系统疾病是该地区医疗保健负担的主要原因之一，而哮喘是影响许多美国人生活质量的主要疾病之一。 根据美国过敏、哮喘和免疫学会 (ACAAI) 组织 2023 年 1 月的更新，美国每年有 439,000 例与哮喘相关的住院治疗和近 130 万例哮喘就诊。 此外，如上所述，该国每年与哮喘相关的经济成本为 560 亿美元。
此外，根据 Lung Canada 组织 2023 年 1 月的更新，加拿大是哮喘患病率和发病率最高的国家，每年约有 270 万加拿大人患有哮喘。 此外，如上述来源所述，哮喘和儿童住院是与工作时间损失和缺勤相关的第三大最重要因素。 预计此类疾病的高患病率将增加对 NIV 的需求并推动该地区的市场增长。
无创呼吸机行业概况
全球无创呼吸机市场竞争激烈，由许多大型企业组成。 主要参与者正专注于推出新产品并扩大其产品组合。 全球和区域参与者专注于战略活动，例如伙伴关係、协作和收购。 全球市场的一些公司有ResMed Inc.、Teleflex Incorporated、Hamilton Bonaduz AG、HEYER Medical AG、Koninklijke Philips N.V.等。
其他福利：
- Excel 格式的市场预测 (ME) 表
- 3 个月的分析师支持
内容
第一章介绍
- 调查假设和市场定义
- 本次调查的范围
第二章研究方法论
第 3 章执行摘要
第四章市场动态
- 市场概览
- 市场驱动力
- 呼吸系统疾病的患病率增加
- 慢性病患者人数增加，重症监护住院人数增加
- 市场製约因素
- 呼吸机相关性肺炎的风险
- 波特五力
- 新进入者的威胁
- 买方/消费者议价能力
- 供应商的议价能力
- 替代品的威胁
- 竞争公司之间的敌对关係
第 5 章市场细分（基于价值的市场规模）
- 按产品分类
- 无创正压通气 (PPV)
- 双水平气道正压 (BiPAP)
- 常规气道正压呼吸器 (CPAP)
- 自动滴定（调整）气道正压呼吸机 (APAP)
- 负压通气 (NPV)
- 无创正压通气 (PPV)
- 通过使用
- COPD 和支气管哮喘
- 呼吸窘迫综合征
- 其他
- 最终用户
- 医院和诊所
- 门诊手术中心
- 其他
- 地区
- 北美
- 美国
- 加拿大
- 墨西哥
- 欧洲
- 德国
- 英国
- 法国
- 意大利
- 西班牙
- 其他欧洲
- 亚太地区
- 中国
- 日本
- 印度
- 澳大利亚
- 韩国
- 其他亚太地区
- 中东和非洲
- 海湾合作委员会
- 南非
- 其他中东和非洲地区
- 南美洲
- 巴西
- 阿根廷
- 其他南美洲
- 北美
第6章竞争格局
- 公司简介
- ResMed Inc.
- Teleflex Incorporated
- Hamilton Bonaduz AG
- heyer medical AG
- Koninklijke Philips N.V.
- Airon Corporation
- Fisher & Paykel Healthcare
- Mindray Medical International Limited
- Phoenix Medical Systems Pvt. Ltd.
- Smiths Medical, Inc.
- Dragerwerk AG & Co. KGaA
- Getinge AB
第7章 市场机会与将来动向
The non-invasive ventilators (NIV) market is expected to register a CAGR of 5.9% over the forecast period.
The onset of the COVID-19 pandemic had a significant impact on the market studied. Due to the sudden onset of the pandemic, a short-term negative impact was initially seen on the market, owing to the decreased patient visits to hospitals and clinics. However, the market witnessed immense growth in the later phases of the pandemic due to increased demand for NIV for COVID-19 patients and other chronic respiratory disease patients. As per a research study published in the Clinical Respiratory Journal in March 2021, along with continuous positive airway pressure (CPAP), NIV was widely used to treat patients with moderate to severe acute respiratory failure (ARF). Also, the researchers concluded that when a group of patients with moderate to severe COVID-19 infection were studied, NIV was successful in 48% of the total studied population, and a 57% survival rate was seen among the patients in the intensive care unit (ICU) incubation after NIV. Thus, due to the high survival rate among the target patients, the demand for the NIVs increased. This significantly contributed to the market's growth and is further expected to continue its growth trend during the forecast period.
Factors such as increasing cases of respiratory disorders and a rapid increase in demand for non-invasive procedures are anticipated to fuel the market growth during the forecast period. In addition, advantages associated with various types of non-invasive (NIV) ventilators are other factors associated with the increasing adoption of the devices and garnering the market's growth.
Chronic respiratory diseases affect the airways and other parts of the lungs. Respiratory symptoms are among the major causes of consultation with doctors and physicians in primary healthcare centers. Some of the major preventable chronic respiratory disorders are asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, sleep apnea, and tuberculosis (principally, multi-drug resistant tuberculosis). These patients require ventilation for a better outcome. According to an article published in NCBI in June 2022, non-invasive positive pressure ventilation delivers oxygen into the lungs via positive pressure without the need for endotracheal intubation and is used in both acute and chronic respiratory failure.
In addition, as per an article published in the LLICM in June 2022, in post-operative hypoxemia, NIV has been successfully used. In addition, facemask NIV is known to improve gas exchange, reduce breathing issues and improve clinical outcomes in patients with hypercapnic respiratory failure due to chronic obstructive pulmonary disease (COPD), obesity-hypoventilation, and in patients with cardiogenic pulmonary edema. Thus, due to the associated benefits of the systems, the adoption of these devices is increasing and expected to fuel the growth of the market.
However, complications and side effects associated with ventilators, such as the risk of being affected with pneumonia, might lower the adoption of the products, hindering the market's growth.
Non-invasive Ventilators Market Trends
COPD and Asthma is Expected to Witness Significant Growth During the Forecast Period
COPD is a progressive life-threatening lung disease that causes breathlessness (initially with exertion) and predisposes to exacerbations. Moreover, serious illness may lead to an increasing need for emergency treatment for prolonged periods. In addition, asthma is one of the most common but complex heterogeneous inflammatory airway disorders seen among the target population. Thus, due to a high number of respiratory emergencies such as asthma and COPD, the application of NIV is expected to increase, thereby accelerating segmental growth.
According to an article published in the American Journal of Respiratory and Critical Care Medicine in September 2022, nearly 1 in 10 people are affected by COPD every year globally. In addition, as per the data published by the Global Initiative for Chronic Obstructive Lung Disease on World Lung Day 2022, nearly an estimated 200 million people had COPD in the previous year, and asthma is one of the most common respiratory diseases which affects approximately 262 million people annually. Various research suggests that NIV has more positive benefits for populations with asthma and COPD. Thus, the high burden of diseases is anticipated to create demand for the adoption of NIV and fuel the segment growth.
Additionally, according to an article published in the American Journal of Translational Research (AJTR) in May 2022, ipratropium bromide combined with non-invasive ventilation is effective in the treatment of patients with COPD and respiratory failure. The systems can significantly ameliorate circulatory inflammation and improve the pulmonary function and blood gas levels of patients and provide higher treatment efficacy. Thus, these benefits of the systems are anticipated to fuel the segment growth over the forecast period. Therefore, the advantages of the systems and applications in treating COPD patients are anticipated to create competitiveness among the players and contribute to the segment's growth.
North America is Expected to Hold a Significant Share of the Market Over the Forecast Period
North America is expected to hold a major share of the market, and it is predicted to continue its growth over the forecast period. The major factors fuelling the market growth in the region are the increasing prevalence of various respiratory diseases and the growing number of product approvals.
Respiratory disease is one of the major causes of healthcare burden in the region, and asthma is one of the major diseases that affect the quality of life for most Americans. According to the January 2023 update by the American College of Allergy, Asthma & Immunology (ACAAI) organization, the annual hospitalization related to asthma is 439,000, and asthma accounts for nearly 1.3 million emergency room visits annually in the United States. In addition, as per the source above, the economic cost related to asthma is USD 56,000 million annually in the country.
Additionally, as per the January 2023 update by the Lung Canada organization, the rate of prevalence and incidence of asthma is among the highest in Canada, and about 2.7 million Canadians live with asthma every year. Also, as per the source above, asthma is the third crucial factor related to work time lost and school absenteeism coupled with hospitalization for children. The high prevalence of the diseases is anticipated to increase demand for NIV, thereby driving market growth in the region.
Non-invasive Ventilators Industry Overview
The global non-invasive ventilators market is highly competitive and consists of a number of major players. The major companies are focused on new product launches and the expansion of their product portfolio. The global and regional players focus on strategic activities such as partnership, collaboration, and acquisition. A few companies in the global market are ResMed Inc., Teleflex Incorporated, Hamilton Bonaduz AG, HEYER Medical AG, and Koninklijke Philips N.V., among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increased Prevalence of Respiratory Disorders
- 4.2.2 High Incidences of Chronic Conditions and Increasing Intensive Care Admissions
- 4.3 Market Restraints
- 4.3.1 Risk of Ventilator-Associated Pneumonia
- 4.4 Porter Five Forces
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
- 5.1 By Product
- 5.1.1 Non-invasive Positive-pressure Ventilator (PPV)
- 5.1.1.1 Bi-level Positive Airway Pressure Ventilator (BiPAP)
- 5.1.1.2 Constant Positive Airway Pressure Ventilator (CPAP)
- 5.1.1.3 Autotitrating (Adjustable) Positive Airway Pressure Ventilator (APAP)
- 5.1.2 Non-invasive Negative Pressure Ventilator (NPV)
- 5.1.1 Non-invasive Positive-pressure Ventilator (PPV)
- 5.2 By Application
- 5.2.1 COPD and Asthma
- 5.2.2 Respiratory Distress Syndrome
- 5.2.3 Others
- 5.3 End Users
- 5.3.1 Hospitals and Clinics
- 5.3.2 Ambulatory Surgical Centers
- 5.3.3 Others
- 5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
- 5.4.1 North America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 ResMed Inc.
- 6.1.2 Teleflex Incorporated
- 6.1.3 Hamilton Bonaduz AG
- 6.1.4 heyer medical AG
- 6.1.5 Koninklijke Philips N.V.
- 6.1.6 Airon Corporation
- 6.1.7 Fisher & Paykel Healthcare
- 6.1.8 Mindray Medical International Limited
- 6.1.9 Phoenix Medical Systems Pvt. Ltd.
- 6.1.10 Smiths Medical, Inc.
- 6.1.11 Dragerwerk AG & Co. KGaA
- 6.1.12 Getinge AB
